

U.S.S.N. 09/776,574

-2-


CM2-104033-006 (CAYMAN 0101 PUS)

**IN THE CLAIMS:**

1-5. (Cancelled)

6. (Previously Presented) A method of treating increased intraocular pressure in the eye of a human or animal comprising the step of:

administering a therapeutically effective amount of at least one compound of the general formula to the eye:

**Formula I**

wherein X is O, S, NH or CH<sub>2</sub>;

R<sub>1</sub> and R<sub>2</sub> are the same and are either H, CH<sub>3</sub> or F;

R<sub>9</sub> is H, or C<sub>1</sub>-C<sub>20</sub> straight chain, saturated or unsaturated or branched acyl;

R<sub>11</sub> is H, or C<sub>1</sub>-C<sub>20</sub> straight chain, saturated or unsaturated or branched acyl;

--- represents any combination of a single bond, or a cis or trans double bond;

Z is H, Cl, Br, I, CF<sub>3</sub>, CH<sub>3</sub>, or C<sub>1</sub>-C<sub>10</sub> straight chain or branched alkyl;

Y is O, S, NH or CH<sub>2</sub>.


7. (Original) The method of claim 6 wherein the compound is selected from the group consisting of a 1,15-lactone of fluprostenol, a 1,15-lactone of cloprostenol, and a 1,15-lactone of latanoprost.

8. (Previously Presented) A topical ophthalmic composition for treating increased intraocular pressure comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one compound of the general formula:

U.S.S.N. 09/776,574

-3-

CM2-104033-006 (CAYMAN 0101 PUS)



Formula I

wherein X is O, S, NH or CH<sub>2</sub>;

R<sub>1</sub> and R<sub>2</sub> are the same and are either H, CH<sub>3</sub> or F;

R<sub>9</sub> is H, or C<sub>1</sub>-C<sub>20</sub> straight chain, saturated or unsaturated or branched acyl;

R<sub>11</sub> is H, or C<sub>1</sub>-C<sub>20</sub> straight chain, saturated or unsaturated or branched acyl;

--- represents any combination of a single bond, or a cis or trans double bond;

Z is H, Cl, Br, I, CF<sub>3</sub>, CH<sub>3</sub>, or C<sub>1</sub>-C<sub>10</sub> straight chain or branched alkyl;

Y is O, S, NH or CH<sub>2</sub>.

9. (Original) The topical ophthalmic composition of claim 8 wherein the compound is selected from the group consisting of a 1, 15-lactone of fluprostenol, a 1,15-lactone of cloprostenol, and a 1,15-lactone of latanoprost.

10. (Original) A topical formulation for treating increased intraocular pressure comprising the following ingredients by weight percent:

Fluprostenol 1,15-lactone	0.002
Dextran 70	0.1
Hydroxypropyl Methylcellulose	0.3
Sodium Chloride	0.77
Potassium Chloride	0.12
Disodium EDTA	0.05
Benzalkonium Chloride	0.01
HCl and/or NaOH	to pH=7.0-7.6
Purified water	q.s. to 100%